Merck & Co. is bolstering its oncology pipeline with acquisitions like Terns Pharmaceuticals and Cidara Therapeutics, while Keytruda remains the key growth driver. It expects Keytruda peak sales of $35 billion by 2028 and aims to launch 20 new drugs by 2030.
Major oncology conferences in 2026 include the IASLC World Conference on Lung Cancer in Seoul, the APPOS CAR T-cell therapy dinner in Los Angeles, and the ACP/UKSMO Annual Conference in Birmingham. The events will cover thoracic oncology research, CAR T-cell toxicity management, and medical oncology workforce development.
The FDA approved Orca-T (Tregzi) for matched donor hematopoietic stem cell transplantation in adults with hematologic malignancies. Phase 3 Precision-T data showed reduced graft-versus-host disease across leukemia and MDS populations, with experts calling it a 'big advance' requiring further comparison with post-transplant cyclophosphamide.
Hematologic cancer survivors face elevated CVD risk and fourfold higher heart failure risk. Cardiac screening is low among cardiotoxic treatment recipients. A trial found simple risk assessment may suffice.
CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.
New market reports forecast significant expansion in CAR T-cell therapy, US pharmaceutical drug delivery, and healthcare nanotechnology sectors, driven by chronic disease prevalence and technological advances.
For the first time, 70% of cancer patients in the U.S. survive five years or more after diagnosis, according to the American Cancer Society's 2026 report. Advances in immunotherapy, CAR T-cell therapy, and screening technologies have driven significant improvements, particularly for lung cancer and myeloma. The definition of successful cancer care is evolving beyond survival to focus on quality of life and durable remissions.
The CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%. The Cell & Gene Therapy Drug Delivery Devices Market is forecast to climb to USD 26.79 billion by 2032 from USD 3.39 billion in 2025.
The global stem cell therapy market is projected to grow from $18.13 billion in 2025 to $59.70 billion by 2035 at a 12.66% CAGR, driven by chronic disease prevalence and regenerative medicine advances.
Recent advances in chimeric antigen receptor cell therapies highlight improved designs for CAR-T and CAR-NK treatments, with new strategies addressing efficacy and safety challenges in both hematologic and solid tumors.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07756034 |
Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer |
RECRUITING | |
| NCT07714044 |
Rutgers University Study of the Genetics of Blood Cancers |
NOT_YET_RECRUITING | |
| NCT07709013 |
Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients |
RECRUITING | PHASE2 |
| NCT07709000 |
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07653672 |
Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia |
NOT_YET_RECRUITING | |
| NCT07590648 |
Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia |
NOT_YET_RECRUITING | PHASE4 |
| NCT07441967 |
The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation |
NOT_YET_RECRUITING | PHASE2 |
| NCT07359859 |
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant |
RECRUITING | PHASE2 |
| NCT07346105 |
Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies |
AVAILABLE | |
| NCT07316907 |
A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies |
NOT_YET_RECRUITING | PHASE1 |
